News

Under the terms of the agreement, CICT will utilize Cesca’s newest evolution of the AutoXpress® platform under the Company’s "Early Technology Access Program". Specifically, this latest innovation of

These formulations will be compared against an immediate release oral solution of drug candidate OCR-002 and ammonia-lowering agent glycerol phenylbutrate (RAVICTI®), a pre-pro drug of phenylacetate, a component

No adverse effects on cognition or emotional stability and no abuse potential were indicated with BNC210 reducing the effect of nicotine. The company enrolled 54 healthy volunteers and

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

The companies will advance new therapies that function via the ubiquitin proteasome system (UPS) for modulating protein homeostasis, a fundamental cellular process controlling protein levels. Celgene will pay

The breakthrough therapy designation is given to speed up the development and review of medicines with early signals of possible clinical benefit in serious diseases to make sure

The companies will work together in developing and commercializing novel therapeutics in the fields of cancer immunotherapy and inflammation. Amgen agreed to pay $45m upfront to license Xencor’s

The company carried out the trial at 12 sites in the US with 450 patients randomized to receive either ITI-007 60 mg or 40 mg or placebo once

GBR 1302 is a HER2xCD3 bi-specific antibody based on Glenmark’s BEAT platform. The drug candidate has the potential to be used in the treatment of an array of